Featured Publications
High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq
Liu Y, DiStasio M, Su G, Asashima H, Enninful A, Qin X, Deng Y, Nam J, Gao F, Bordignon P, Cassano M, Tomayko M, Xu M, Halene S, Craft J, Hafler D, Fan R. High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq. Nature Biotechnology 2023, 41: 1405-1409. PMID: 36823353, PMCID: PMC10567548, DOI: 10.1038/s41587-023-01676-0.Peer-Reviewed Original ResearchIRF8 in Conjunction With CD123 and CD20 to Distinguish Lupus Erythematosus Panniculitis From Subcutaneous Panniculitis-like T-Cell Lymphoma
Wong J, Roy S, McNiff J, Xu M. IRF8 in Conjunction With CD123 and CD20 to Distinguish Lupus Erythematosus Panniculitis From Subcutaneous Panniculitis-like T-Cell Lymphoma. The American Journal Of Surgical Pathology 2023, 47: 1425-1431. PMID: 37767989, DOI: 10.1097/pas.0000000000002133.Peer-Reviewed Original ResearchConceptsSubcutaneous panniculitis-like T-cell lymphomaLupus erythematosus panniculitisPanniculitis-like T-cell lymphomaCase of SPTCLT-cell lymphomaPlasmacytoid dendritic cell differentiationPlasmacytoid dendritic cellsExpression of IRF8Dendritic cell differentiationCharacteristic curve analysisImportant clinical implicationsRegulatory factor 8Dendritic cellsCutaneous biopsyLymphoid aggregatesDiagnostic challengeImmunohistochemical panelImmunohistochemical expressionCD123CD20Distinct patientsClinical implicationsSubcutaneous fatDiagnostic testsPositive markersTissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients
Baraban E, Hu S, Hui P, Podoltsev N, Cooper D, Xu M. Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients. Bone Marrow Transplantation 2016, 52: 634-637. PMID: 27991892, DOI: 10.1038/bmt.2016.332.Peer-Reviewed Original ResearchEmerging Immunohistochemical Biomarkers for Myeloid Neoplasms.
Verma A, Xu ML. Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms. Archives Of Pathology & Laboratory Medicine 2022, 147: 403-412. PMID: 35533352, DOI: 10.5858/arpa.2021-0558-ra.Peer-Reviewed Original ResearchConceptsMyeloid neoplasmsImmunohistochemical biomarkersImmunohistochemical markersManagement of patientsNovel immunohistochemical markerPosttreatment biopsiesImmunohistochemical toolsDisease progressionCorrect diagnosisClinical scenariosNeoplasmsPatient careLiterature searchRelevant biomarkersBiomarkersImmunohistochemistryMolecular biomarkersScientific literature searchMarkersArchival samplesOriginal articlesMolecular eraCurrent eraPatientsBiopsyGlobal assessment of IRF8 as a novel cancer biomarker
McQuaid DC, Panse G, Wang WL, Pinkus GS, Katz SG, Xu ML. Global assessment of IRF8 as a novel cancer biomarker. Human Pathology 2022, 122: 1-10. PMID: 35085599, PMCID: PMC10621657, DOI: 10.1016/j.humpath.2022.01.004.Peer-Reviewed Original ResearchConceptsBlastic plasmacytoid dendritic cell neoplasmInterferon regulatory factor 8Myeloid sarcomaDifferential diagnosisPlasmacytoid dendritic cell neoplasmDesmoplastic small round cell tumorSmall round cell tumorTriple-negative breast cancerStrong uniform expressionDendritic cell neoplasmBroad differential diagnosisNegative breast cancerRound cell tumorAbsence of CD34IHC expression patternsAcute monocytic leukemiaNovel immunohistochemical markerTypes of cancerRegulatory factor 8Cancer Genome AtlasNovel cancer biomarkersRetrospective studySynovial sarcomaCell tumorsPleomorphic sarcomaExpression of CD30 as a biomarker to predict response to brentuximab vedotin
Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.Peer-Reviewed Original ResearchEpithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping
Xu ML, Yang B, Carcangiu ML, Hui P. Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping. Modern Pathology 2008, 22: 232-238. PMID: 18820674, DOI: 10.1038/modpathol.2008.165.Peer-Reviewed Original ResearchMeSH KeywordsAdultCarcinoma, Squamous CellComparative Genomic HybridizationDiagnosis, DifferentialEndometrial NeoplasmsEpithelioid CellsFemaleGene Expression Regulation, NeoplasticGenetic TestingGenotypeGestational Trophoblastic DiseaseHumansItalyLung NeoplasmsMiddle AgedPregnancyUnited StatesUterine Cervical NeoplasmsConceptsEpithelioid trophoblastic tumorTrophoblastic tumorSquamous cell carcinomaUterine cervixComparative genomic hybridizationCommon squamous cell carcinomaChromosomal alterationsInvasive squamous cell carcinomaChorionic-type intermediate trophoblastGestational trophoblastic diseaseGenomic hybridizationDNA genotypingIntermediate trophoblastTrophoblastic diseaseAnatomic locationComparative genomic hybridization analysisTrophoblastic originTumorsGenomic hybridization analysisCervixNormal tissuesTrophoblastic natureConventional comparative genomic hybridizationCarcinomaChromosomal profileDendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma
Pelland K, Mathews S, Kamath A, Cohen P, Hudnall SD, Cotta CV, Xu ML. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma. Applied Immunohistochemistry & Molecular Morphology 2018, 26: e101-e106. PMID: 29189264, DOI: 10.1097/pai.0000000000000615.Peer-Reviewed Original ResearchConceptsPrimary mediastinal large B-cell lymphomaMediastinal gray zone lymphomaClassic Hodgkin lymphomaGray zone lymphomaPD-L1Mediastinal large B-cell lymphomaLarge B-cell lymphomaDendritic cell markersB-cell lymphomaCell gene expression profilesHodgkin's lymphomaRare entityCD123LymphomaTherapeutic potentialCell markersTherapeutic significanceGenetic featuresGene expression profilesFascinRepresentative sectionsExpression profilesImmunohistochemistryTumorsDiagnosisHistopathologic and Machine Deep Learning Criteria to Predict Lymphoma Transformation in Bone Marrow Biopsies.
Irshaid L, Bleiberg J, Weinberger E, Garritano J, Shallis RM, Patsenker J, Lindenbaum O, Kluger Y, Katz SG, Xu ML. Histopathologic and Machine Deep Learning Criteria to Predict Lymphoma Transformation in Bone Marrow Biopsies. Archives Of Pathology & Laboratory Medicine 2021, 146: 182-193. PMID: 34086849, DOI: 10.5858/arpa.2020-0510-oa.Peer-Reviewed Original ResearchConceptsLarge cell transformationChronic lymphocytic leukemiaBone marrow biopsyMarrow biopsyFollicular lymphomaIndolent B-cell lymphomaLarge lymphoma cellsClinical disease progressionDiagnosis of FLFinal outcome dataB-cell lymphomaLarge tumor cellsEase of procedureAggressive chemotherapyLow morbidityLymph nodesWorse prognosisWhole slide scansHistologic findingsPatient's probabilityDisease progressionLymphocytic leukemiaLymphoma transformationClinical questionsOutcome data
2024
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Evens A, Naik S, Kamdar M, Haverkos B, Karmali R, Farooq U, Vose J, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Advances 2024, 8: 5355-5364. PMID: 39189932, PMCID: PMC11568788, DOI: 10.1182/bloodadvances.2024013791.Peer-Reviewed Original ResearchBaseline CNS involvementCentral nervous system recurrenceHigh-grade B-cell lymphomaCentral nervous systemB-cell lymphomaCNS involvementCNS recurrenceIncidence of CNS recurrenceRisk of CNS recurrenceCentral nervous system involvementMulti-institutional seriesNon-GCB subtypeBone marrow involvementMulticenter retrospective studyCNS-IPIRisk factor analysisMarrow involvementMYC rearrangementNon-GCBPrimary therapyCD5 expressionAutologous transplantationSurvival outcomesNo significant differenceNOS patientsData-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, Travaglino E, Al Ali N, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain A, Aguirre L, Tinsley-Vance S, Schwabkey Z, Chan O, Xie Z, Brunner A, Kuykendall A, Bennett J, Buckstein R, Bejar R, Carraway H, DeZern A, Griffiths E, Halene S, Hasserjian R, Lancet J, List A, Loghavi S, Odenike O, Padron E, Patnaik M, Roboz G, Stahl M, Sekeres M, Steensma D, Savona M, Taylor J, Xu M, Sweet K, Sallman D, Nimer S, Hourigan C, Wei A, Sauta E, D’Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate U, Sanz G, Efficace F, Gore S, Kim T, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang A, Foucar M, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht A, Ades L, Zeidan A, Della Porta M, Syndromes I. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. The Lancet Haematology 2024, 11: e862-e872. PMID: 39393368, DOI: 10.1016/s2352-3026(24)00251-5.Peer-Reviewed Original ResearchGenomic featuresData-driven approachTP53 inactivationGenomic heterogeneityEntity labelsGenetic featuresDel(7q)/-7Myelodysplastic syndromeGenomic profilingData scientistsMutated SF3B1Cluster assignmentComplex karyotypeRUNX1 mutationsModified Delphi consensus processDel(5qIsolated del(5qAcute myeloid leukemiaData-drivenDelphi consensus processMarrow blastsSpatially exploring RNA biology in archival formalin-fixed paraffin-embedded tissues
Bai Z, Zhang D, Gao Y, Tao B, Zhang D, Bao S, Enninful A, Wang Y, Li H, Su G, Tian X, Zhang N, Xiao Y, Liu Y, Gerstein M, Li M, Xing Y, Lu J, Xu M, Fan R. Spatially exploring RNA biology in archival formalin-fixed paraffin-embedded tissues. Cell 2024, 187: 6760-6779.e24. PMID: 39353436, PMCID: PMC11568911, DOI: 10.1016/j.cell.2024.09.001.Peer-Reviewed Original ResearchRNA biologyWhole-transcriptome sequencingMicroRNA regulatory networkSplicing dynamicsDeterministic barcodingRNA speciesRNA processingRNA variantsFFPE tissuesRegulatory networksTranscriptome sequencingSpliced isoformsNon-malignant cellsTumor clonal architecturesClonal architectureGene expressionCellular dynamicsRNAArchival formalin-fixed paraffin-embedded tissueMalignant subclonesFormalin-fixed paraffin-embedded (FFPEFFPE samplesParaffin-embedded (FFPEBiologyHuman lymphomasContemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])
Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, DeZern A, Efficace F, Fenaux P, Figueroa M, Garcia-Manero G, Gore S, Greenberg P, Griffiths E, Halene S, Hourigan C, Kim T, Kim N, Komrokji R, Kutchroo V, List A, Little R, Majeti R, Nazha A, Nimer S, Odenike O, Padron E, Patnaik M, Platzbecker U, Della Porta M, Roboz G, Sallman D, Santini V, Sanz G, Savona M, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Wei A, Xie Z, Xu M, Hasserjian R, Loghavi S. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Modern Pathology 2024, 37: 100615. PMID: 39322118, DOI: 10.1016/j.modpat.2024.100615.Peer-Reviewed Original ResearchLarge B‐cell lymphoma with mystery rearrangement: Applying Hi‐C to the detection of clinically relevant structural abnormalities
Prior D, Schmitt A, Louissaint A, Mata D, Massaro S, Nardi V, Xu M. Large B‐cell lymphoma with mystery rearrangement: Applying Hi‐C to the detection of clinically relevant structural abnormalities. British Journal Of Haematology 2024, 205: 1225-1229. PMID: 38924537, DOI: 10.1111/bjh.19611.Peer-Reviewed Original ResearchLiquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results
Mata D, Lee J, Shanmugam V, Marcus C, Schrock A, Williams E, Ritterhouse L, Hickman R, Janovitz T, Patel N, Kroger B, Ross J, Mirza K, Oxnard G, Vergilio J, Elvin J, Benhamida J, Decker B, Xu M. Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology 2024, 84: 1224-1237. PMID: 38422618, DOI: 10.1111/his.15168.Peer-Reviewed Original ResearchConceptsNon-Hodgkin's lymphomaPlasma-cell neoplasmsAcute myeloid leukemiaCirculating tumor DNAHodgkin lymphomaMyelodysplastic syndromeHaematopoietic neoplasmsNext-generation sequencingTissue-based NGSMaximum somatic allele frequencyFoundationOne Liquid CDxTherapy-resistant clonesRelevant genomic alterationsPositive percent agreementPotential clinical utilityLymphoid malignanciesTumor DNAMyeloid leukemiaPlasma-cellsTissue biopsiesGenomic alterationsPathogenic alterationsLiquid biopsyMolecular profilingTP53PD-1H/VISTA mediates immune evasion in acute myeloid leukemia
Kim T, Han X, Hu Q, Vandsemb E, Fielder C, Hong J, Kim K, Mason E, Plowman R, Wang J, Wang Q, Zhang J, Badri T, Sanmamed M, Zheng L, Zhang T, Alawa J, Lee S, Zeidan A, Halene S, Pillai M, Chandhok N, Lu J, Xu M, Gore S, Chen L. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia. Journal Of Clinical Investigation 2024, 134 PMID: 38060328, PMCID: PMC10836799, DOI: 10.1172/jci164325.Peer-Reviewed Original ResearchGenetics and pathologic landscape of lineage switch of acute leukemia during therapy
Zhou T, Curry C, Khanlari M, Shi M, Cui W, Peker D, Chen W, Wang E, Gao J, Shen Q, Xie W, Jelloul F, King R, Yuan J, Wang X, Zhao C, Obiorah I, Courville E, Nomura E, Cherian S, Xu M, Burack W, Liu H, Jabbour E, Takahashi K, Wang W, Wang S, Khoury J, Medeiros L, Hu S. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood Cancer Journal 2024, 14: 19. PMID: 38272888, PMCID: PMC10810851, DOI: 10.1038/s41408-024-00983-2.Peer-Reviewed Original Research
2023
Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype
Verma A, Liburd S, Tobias Z, Isufi I, Pober J, Xu M. Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype. Blood 2023, 142: 2075. DOI: 10.1182/blood-2023-184963.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaPre-treatment biopsiesVenular endothelial cellsLarge B-cell lymphomaMemory T cellsHigh endothelial venulesT cellsB-cell lymphomaVCAM-1E-selectinICAM-1Endothelial cellsChimeric antigen receptor T-cell therapyL-selectinPre-treatment tumor biopsiesEffector memory T cellsCentral memory T cellsCAR T-cell therapyCell therapyHEV endothelial cellsInflamed lymph nodesT-cell infiltratesT cell exhaustionT-cell therapyT-cell homingAn agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kutchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Advances 2023, 7: 2709-2714. PMID: 36260702, PMCID: PMC10333740, DOI: 10.1182/bloodadvances.2022008747.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsIRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression
Tang H, Panse G, Braddock D, Perincheri S, Xu M, McNiff J. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression. Journal Of Cutaneous Pathology 2023, 50: 595-600. PMID: 37082914, DOI: 10.1111/cup.14439.Peer-Reviewed Original ResearchConceptsBlastic plasmacytoid dendritic cell neoplasmPlasmacytoid dendritic cell neoplasmDendritic cell neoplasmPunch biopsy specimenBiopsy specimenCell neoplasmsCase of BPDCNUseful markerTumor cellsTCL-1 expressionAtypical mononuclear cellsBone marrow involvementDiffuse dermal infiltrateDendritic cell lineagePotential diagnostic pitfallRegulatory factor 8TCL-1BPDCN casesCD123 expressionMarrow involvementDermal infiltrateCutaneous nodulesMyelodysplastic syndromeSkin nodulesMononuclear cells